Thymoma Clinical Trial
Official title:
Prospective Ⅱ Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment
For patients with unresectable or recurrent disease, radiation is routinely administered, often in combination with systemic chemotherapy. However, because of wide range of radiation, more complications of conventional radiotherapy limit its treatment dose. The local recurrence rates of conventional radiotherapy are dissatisfied.Stereotactic body radiation therapy(SBRT) well solved the problem above. On the one hand, by improving the single dose, it not only shortens the total radiation treatment, but also increases the total dose of equivalent biological effects.
Thymoma is mainly divided into two types, invasive and noninvasive type, and more than 60% of patients belong to noninvasive thymoma. When feasible, complete surgical resection is the primary treatment. There are quite a number of thymoma patients that has lost its surgical indications when diagnosed. Even after complete resection, the recurrence rate can be about 20%. For patients with unresectable or recurrent disease, radiation is routinely administered, often in combination with systemic chemotherapy. However, because of wide range of radiation, more complications of conventional radiotherapy limit its treatment dose. The local recurrence rates of conventional radiotherapy are up 16% to 45%. Moreover, it's not suitable for patients with severe heart and lung disease. Stereotactic body radiation therapy(SBRT) well solved the problem above. On the one hand, by improving the single dose, it not only shortens the total radiation treatment, but also increases the total dose of equivalent biological effects; On the other hand, SBRT, with more precise conformal radiation therapy, significantly reduces the damage to the surrounding normal tissues. Theoretically, SBRT can improve the local control, as well greatly reduces incidence of the radiation pneumonia, pericarditis, tracheitis, esophagitis and so on. However, few studies focused on the treatment of thymoma by SBRT, except two case reports Here we performed a prospective study on the treatment of thymoma by SBRT. The purpose of this prospective study was a preliminary evaluation of feasibility, efficacy and toxicity ofγ-SBRT in the treatment of thymoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
Completed |
NCT00332969 -
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
|
Phase 2 | |
Completed |
NCT00921739 -
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
|
Phase 1 | |
Recruiting |
NCT05255965 -
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
|
||
Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
Completed |
NCT00387868 -
Preoperative Treatment of Patients With High Risk Thymoma
|
Phase 2 | |
Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A | |
Recruiting |
NCT03466827 -
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
Completed |
NCT02220855 -
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
|
Phase 2 | |
Completed |
NCT03288662 -
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
|
N/A | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
Recruiting |
NCT06029621 -
Robot-assisted vs VATS for Thymoma
|
N/A | |
Active, not recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
Active, not recruiting |
NCT01621568 -
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
|
Phase 2 | |
Recruiting |
NCT05262582 -
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
|
N/A | |
Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03968315 -
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
|
N/A | |
Recruiting |
NCT04162691 -
Single Cell Sequencing Analysis of Thymoma
|
||
Recruiting |
NCT06086327 -
Application of 68Ga-Pentixafor PET/CT for Thymoma
|
Early Phase 1 |